Home Stock

Stock Research: Penumbra

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Penumbra

NYQ:PEN US70975L1070
37
  • Value
    4
  • Growth
    65
  • Safety
    Safety
    92
  • Combined
    56
  • Sentiment
    13
  • 360° View
    360° View
    37
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Penumbra, Inc. is a thrombectomy company focused on developing technologies for challenging medical conditions by removing blood clots. Its main businesses include developing, manufacturing, and marketing novel products for conditions such as ischemic stroke, venous thromboembolism, acute limb ischemia, and acute coronary syndrome. The company operates in the United States, Europe, Canada, and Australia. In the last fiscal year, the company had 4500 employees, a market cap of $9155 million, profits of $755 million, and revenue of $1195 million.

more

ANALYSIS: With an Obermatt 360° View of 37 (better than 37% compared with alternatives), overall professional sentiment and financial characteristics for the stock Penumbra are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Penumbra. The consolidated Growth Rank has a good rank of 65, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 65% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 92 which means that the company has a financing structure that is safer than 92% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 4 which means that the share price of Penumbra is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 96% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 13, which means that professional investors are more pessimistic about the stock than for 87% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Liquidity
Country USA
Industry Health Care Equipment
Size Large
Website penumbrainc.com
Index
D.J. US Health Care
D.J. US Medical Equipment
S&P MIDCAP
Penumbra stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 7 8 11
Growth
65 77 89 81
Safety
Safety
92 98 85 85
Sentiment
13 79 87 84
360° View
360° View
37 91 70 64
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
13 69 55 88
Opinions Change
47 21 50 75
Pro Holdings
n/a 75 60 10
Market Pulse
38 95 97 87
Sentiment
13 79 87 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 7 8 11
Growth
65 77 89 81
Safety Safety
92 98 85 85
Combined
56 81 57 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
9 16 17 28
Price vs. Earnings (P/E)
3 15 20 12
Price vs. Book (P/B)
17 27 26 28
Dividend Yield
1 1 1 1
Value
4 7 8 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
67 61 62 43
Profit Growth
72 94 100 100
Capital Growth
9 45 48 63
Stock Returns
77 59 79 71
Growth
65 77 89 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
76 82 68 77
Refinancing
45 22 7 11
Liquidity
95 98 13 13
Safety Safety
92 98 85 85

Similar Stocks

Discover high‑ranked alternatives to Penumbra and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

M/I Homes

NYQ:MHO
Country: USA
Industry: Homebuilding
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews